NORTH CHICAGO - AbbVie today announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active. | June 1, 2023
By Colin Kellaher AbbVie on Thursday said the Food and Drug Administration has approved the expanded use of its blockbuster immunology drug Rinvoq for adults with moderately to severely active. | May 18, 2023
- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at. | May 9, 2023
AbbVie Inc on Thursday raised its 2023 profit forecast on a less-than-feared hit to U.S. sales of arthritis drug Humira from rival biosimilar drugs.. | April 27, 2023
AbbVie, Inc. is currently at $150.50, down $11.30 or 6.98% Would be lowest close since March 10, 2023, when it closed at $149.71 On pace for largest percent decrease since Sept.. | April 27, 2023